Spectral Medical Past Earnings Performance
Past criteria checks 0/6
Spectral Medical's earnings have been declining at an average annual rate of -20.8%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 19.7% per year.
Key information
-20.8%
Earnings growth rate
-15.8%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -19.7% |
| Return on equity | n/a |
| Net Margin | -970.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate
Feb 12
Spectral Medical Inc.'s (TSE:EDT) Path To Profitability
Mar 28Spectral Medical (TSE:EDT) Is In A Good Position To Deliver On Growth Plans
Feb 21Spectral Medical's(TSE:EDT) Share Price Is Down 49% Over The Past Five Years.
Jan 16Spectral Medical Inc. (TSE:EDT): Is Breakeven Near?
Dec 12
Spectral Medical Inc.'s (TSE:EDT) Shift From Loss To Profit
Aug 02Revenue & Expenses BreakdownBeta
How Spectral Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -16 | 11 | 0 |
| 30 Sep 23 | 2 | -10 | 11 | 0 |
| 30 Jun 23 | 2 | -9 | 10 | 0 |
| 31 Mar 23 | 2 | -7 | 8 | 0 |
| 31 Dec 22 | 2 | -8 | 9 | 0 |
| 30 Sep 22 | 2 | -7 | 6 | 0 |
| 30 Jun 22 | 1 | -7 | 7 | 0 |
| 31 Mar 22 | 2 | -7 | 7 | 0 |
| 31 Dec 21 | 2 | -7 | 7 | 0 |
| 30 Sep 21 | 2 | -8 | 9 | 0 |
| 30 Jun 21 | 2 | -8 | 8 | 0 |
| 31 Mar 21 | 2 | -7 | 8 | 0 |
| 31 Dec 20 | 2 | -9 | 10 | 0 |
| 30 Sep 20 | 2 | -8 | 10 | 0 |
| 30 Jun 20 | 2 | -8 | 10 | 0 |
| 31 Mar 20 | 3 | -7 | 9 | 0 |
| 31 Dec 19 | 3 | -5 | 6 | 0 |
| 30 Sep 19 | 4 | -3 | 6 | 0 |
| 30 Jun 19 | 4 | -2 | 5 | 0 |
| 31 Mar 19 | 3 | -3 | 5 | 0 |
| 31 Dec 18 | 4 | -2 | 5 | 0 |
| 30 Sep 18 | 3 | -4 | 5 | 0 |
| 30 Jun 18 | 3 | -4 | 5 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 4 | -4 | 6 | 0 |
| 30 Sep 17 | 4 | -4 | 6 | 0 |
| 30 Jun 17 | 4 | -6 | 7 | 0 |
| 31 Mar 17 | 3 | -8 | 9 | 0 |
| 31 Dec 16 | 4 | -10 | 11 | 0 |
| 30 Sep 16 | 3 | -11 | 12 | 0 |
| 30 Jun 16 | 3 | -11 | 12 | 0 |
| 31 Mar 16 | 3 | -10 | 11 | 0 |
| 31 Dec 15 | 3 | -10 | 11 | 0 |
| 30 Sep 15 | 3 | -10 | 11 | 0 |
| 30 Jun 15 | 3 | -9 | 10 | 0 |
| 31 Mar 15 | 3 | -9 | 10 | 0 |
| 31 Dec 14 | 3 | -9 | 11 | 0 |
| 30 Sep 14 | 3 | -11 | 13 | 0 |
| 30 Jun 14 | 3 | -12 | 13 | 0 |
| 31 Mar 14 | 3 | -12 | 13 | 0 |
| 31 Dec 13 | 3 | -11 | 12 | 0 |
| 30 Sep 13 | 3 | -10 | 11 | 0 |
| 30 Jun 13 | 3 | -9 | 10 | 0 |
Quality Earnings: EDT is currently unprofitable.
Growing Profit Margin: EDT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EDT is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.
Accelerating Growth: Unable to compare EDT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: EDT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.